Clinical significance of α-fetoprotein: Involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT2, 2008, Pages

  Mitsuhashi, Noboru ^a   Kobayashi, Souichi ^a   Doki, Tomoko ^a   Kimura, Fumio ^a   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Ohtsuka, Masayuki ^a   Kato, Atsushi ^a   Yoshitomi, Hideyuki ^a   Nozawa, Satoshi ^a   Furukawa, Katsunori ^a   Takeuchi, Dan ^a   Suda, Kosuke ^a   Miura, Seiki ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Apoptosis; Hepatocellular carcinoma; Proliferation; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; CD34 ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LIVER CELL CARCINOMA; MALE; MICROVASCULATURE; NICK END LABELING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 47649124110     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05340.x     Document Type: Article

References (52)

1. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006 131 : 461 9.
2. Torimura T, Ueno T, Kin M et al. Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology 2006 130 : 1301 10.
3. Tateishi R, Shiina S, Yoshida H et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006 44 : 1518 27.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999 340 : 745 50.
5. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000 356 : 802 7.
6. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996 334 : 693 9.
7. Matsuura E, Kang Y, Kitakawa H et al. Modulation of T cell function by alpha-fetoprotein: an in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumour Biol. 1999 20 : 162 71.
8. Wang W, Alpert E. Downregulation of phorbol 12-myristate 13-acetate-induced tumor necrosis factor-alpha and interleukin-1 beta production and gene expression in human monocytic cells by human alpha-fetoprotein. Hepatology 1995 22 : 921 8.
9. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004 40 : 609 17.
10. Ruoslahti E, Seppala M Foetoprotein in normal human serum. Nature 1972 235 : 161 2.
11. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int. J. Cancer 1998 75 : 596 9.
12. Okuda K, Kotoda K, Obata H, Hayashi N, Hisamitsu T. Clinical observations during a relatively early stage of hepatocellular carcinoma, with special reference to serum alpha-fetoprotein levels. Gastroenterology 1975 69 : 226 34.
13. Butterfield LH, Ribas A, Dissette VB et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 2006 12 : 2817 25.
14. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev. Anticancer Ther. 2002 2 : 709 35.
15. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 2004 112 : 44 50.
16. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 2000 31 : 302 8.
17. Amemiya H, Kono K, Mori Y et al. High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein. Oncology 2000 59 : 145 51.
18. Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J. Alpha-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis. Am. J. Gastroenterol. 1999 94 : 1658 63.
19. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996 111 : 996 1001.
20. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989 64 : 1700 7.
21. Brumm C, Schulze C, Charels K, Morohoshi T, Kloppel G. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology 1989 14 : 503 13.
22. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 2007 43 : 979 92.
23. Okuda H, Saito A, Shiratori K et al. Clinicopahologic features of patients with primary malignant hepatic tumors seropositive for AFP-L3 alone in comparison with other patients seropositive for AFP-L3. J. Gastroenterol. Hepatol. 2005 20 : 759 64.
24. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 2005 12 : 1175 81.
25. Tateishi R, Shiina S, Yoshida H et al. Prediction of recurrece of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006 44 : 1518 27.
26. Li MS, Ma QL, Chen Q et al. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J. Gastroenterol. 2005 11 : 2564 9.
27. Dudich I, Tokhtamysheva N, Semenkova L, Dudich E, Hellman J, Korpela T. Isolation and structural and functional characterization of two stable peptic fragments of human alpha-fetoprotein. Biochemistry 1999 38 : 10406 14.
28. Liang OD, Korff T, Eckhardt J et al. Oncodevelopmental alpha-fetoprotein acts as a selective proangiogenic factor on endothelial cell from the fetomaternal unit. J. Clin. Endocrinol. Metab. 2004 89 : 1415 22.
29. Arii S, Okamoto E, Imamura M. Registries in Japan: current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan. Semin. Surg. Oncol. 1996 12 : 204 11.
30. Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson's pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery 2001 130 : 443 8.
31. Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expression of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001 34 : 1128 34.
32. Oka H, Saito A, Ito K et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J. Gastroenterol. Hepatol. 2001 16 : 1378 83.
33. Jaskulski D, deRiel JK, Mercer WE, Calabretta B, Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988 240 : 1544 6.
34. Leal JA, Gangrade BK, Kiser JL, May JV, Keel BA. Human mammary tumor cell proliferation: primary role of platelet-derived growth factor and possible synergism with human alpha-fetoprotein. Steroids 1991 56 : 247 51.
35. Shang JB, Li YH, Liu FY et al. 18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein. Di Yi Jun Yi Da Xue Xue Bao 2004 24 : 697 9.
36. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986 46 : 467 73.
37. Poon RT, Ng IO, Lau C et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 2001 233 : 227 35.
38. Kamei S, Kono K, Amemiya H et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J. Gastroenterol. 2003 38 : 540 7.
39. Iida H, Honda M, Kawai HF et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut 2005 54 : 843 51.
40. Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. Alpha-fetoprotein- producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 2001 33 : 676 91.
41. Mitsuhashi N, Shimizu H, Ohtsuka M et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003 37 : 1105 13.
42. Soini Y, Virkajarvi N, Lehto VP, Paakko P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br. J. Cancer 1996 73 : 1025 30.
43. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. I. Selective inhibition of anti-Ia-associated proliferative reactions. J. Exp. Med. 1978 147 : 667 83.
44. Yamada A, Hayami M. Suppression of natural killer cell activity by chicken alpha-fetoprotein in Japanese quails. J. Natl. Cancer Inst. 1983 70 : 735 8.
45. Trevisani F, D'Intino PE, Caraceni P et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995 75 : 2220 32.
46. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998 28 : 751 5.
47. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 1999 31 : 133 41.
48. Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 2006 101 : 513 23.
49. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994 74 : 2772 80.
50. Park JH, Koh KC, Choi MS et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am. J. Surg. 2006 192 : 29 33.
51. Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006 44 : 1543 54.
52. Yao WJ, Chang TT, Wang ST et al. Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma. Oncology 2001 61 : 64 70.